Roivant Sciences, Pfizer form new Vant company focused on developing RVT-3101

Roivant Sciences (ROIV) and Pfizer (PFE) announced formation of a new Vant to develop and commercialize PF-06480605, now RVT-3101. The Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase 1. RVT-3101 has been evaluated in an earlier Phase 2 study in 50 patients, and is being evaluated in a large global Phase 2b study in 245 adult participants with moderate to severe ulcerative colitis. The induction portion of TUSCANY-2 is complete, and the maintenance portion remains ongoing. "Our internally discovered antibody against TL1A, could potentially be the first agent to bring biomarker-selected precision medicine to people living with inflammatory bowel disease," said Mikael Dolsten, Pfizer’s Chief Scientific Officer, President, Worldwide Research, Development and Medical. "We are very excited about the preliminary data from the TUSCANY-2 study and for this new Vant to drive the advancement of this asset." Terms of Collaboration: A new Vant or Roivant subsidiary has been created to develop and fund these programs. The Vant will be fully responsible for funding global development of RVT-3101 in UC and in additional inflammatory and fibrotic diseases and holds commercial rights in the US and Japan. Pfizer owns a 25% equity position in the Vant and maintains commercial rights outside of the US and Japan as well as representation on the company’s Board of Directors. In addition, the Vant has the exclusive option to collaborate with Pfizer on a next-generation TL1A directed antibody which recently entered Phase 1. The Vant will have the right to enter into an agreement for global development with a 50/50 cost share as well as co-commercialization rights with Pfizer prior to Phase 2, expected in 2025.